Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential
Wong, Terrence N., Miller, Christopher A., Jotte, Matthew R. M., Bagegni, Nusayba, Baty, Jack D., Schmidt, Amy P., Cashen, Amanda F., Duncavage, Eric J., Helton, Nichole M., Fiala, Mark, Fulton, Robert S., Heath, Sharon E., Janke, Megan, Luber, Kierstin, Westervelt, Peter, Vij, Ravi, DiPersio, John F., Welch, John S., Graubert, Timothy A., Walter, Matthew J., Ley, Timothy J., Link, Daniel C.
Published in Nature communications (31.01.2018)
Published in Nature communications (31.01.2018)
Get full text
Journal Article
Somatic mutations and clonal hematopoiesis in congenital neutropenia
Xia, Jun, Miller, Christopher A., Baty, Jack, Ramesh, Amrita, Jotte, Matthew R.M., Fulton, Robert S., Vogel, Tiphanie P., Cooper, Megan A., Walkovich, Kelly J., Makaryan, Vahagn, Bolyard, Audrey A., Dinauer, Mary C., Wilson, David B., Vlachos, Adrianna, Myers, Kasiani C., Rothbaum, Robert J., Bertuch, Alison A., Dale, David C., Shimamura, Akiko, Boxer, Laurence A., Link, Daniel C.
Published in Blood (25.01.2018)
Published in Blood (25.01.2018)
Get full text
Journal Article
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
Chen, H, Modiano, M R, Neal, J W, Brahmer, J R, Rigas, J R, Jotte, R M, Leighl, N B, Riess, J W, Kuo, C J, Liu, L, Gao, B, DiCioccio, A T, Adjei, A A, Wakelee, H A
Published in British journal of cancer (04.02.2014)
Published in British journal of cancer (04.02.2014)
Get full text
Journal Article
IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC
Socinski, M.A., Rittmeyer, A., Shapovalov, D., Orlandi, F., McCleod, M., Soo, R.A., Palmero, R., Kozuki, T., Migliorino, M.R., Koynov, K.D., Berard, H., Hughes, B.G.M., Yu, W., Graupner, V., Sun, S.W., Kowanetz, M., Hoang, T., Lin, W., Jotte, R.M.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy
Leal, T.A., Spira, A.I., Blakely, C., He, K., Berz, D., Richards, D., Uyeki, J., Savage, A., Roque, T., Massarelli, E., Jotte, R.M., Chen, I., Christensen, J., Olson, P., Tassell, V., Horn, L.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
Mok, T.S.K., Socinski, M.A., Reck, M., Jotte, R.M., Lim, D.W.-T., Cappuzzo, F., Orlandi, F.J., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Siblot, D., Thomas, C.A., Barlesi, F., Finley, G., Lee, A., Shankar, G., Yu, W., Kowanetz, M., Lin, W., Nishio, M.
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study
Spigel, D.R., Jotte, R.M., Ponce Aix, S., Gressot, L., Morgensztern, D., McCleod, M., Socinski, M.A., Daniel, D., Juan-Vidal, O., Kim, E.S., West, H.J., Chen, T., Bhore, R., Ong, T.J., Gridelli, C., Thomas, M.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
LBA64nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study
Spigel, D R, Jotte, R M, Ponce Aix, S, Gressot, L, Morgensztern, D, McCleod, M, Socinski, M A, Daniel, D, Juan-Vidal, O, Kim, E S, West, H J, Chen, T, Bhore, R, Ong, T J, Gridelli, C, Thomas, M
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1129OStage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy
Leal, T A, Spira, A I, Blakely, C, He, K, Berz, D, Richards, D, Uyeki, J, Savage, A, Roque, T, Massarelli, E, Jotte, R M, Chen, I, Christensen, J, Olson, P, Tassell, V, Horn, L
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
LBA9IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
Mok, T S K, Socinski, M A, Reck, M, Jotte, R M, Lim, D W-T, Cappuzzo, F, Orlandi, F J, Stroyakovskiy, D, Nogami, N, Rodríguez-Abreu, D, Moro-Siblot, D, Thomas, C A, Barlesi, F, Finley, G, Lee, A, Shankar, G, Yu, W, Kowanetz, M, Lin, W, Nishio, M
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
LBA65IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC
Socinski, M A, Rittmeyer, A, Shapovalov, D, Orlandi, F, McCleod, M, Soo, R A, Palmero, R, Kozuki, T, Migliorino, M R, Koynov, K D, Berard, H, Hughes, B G M, Yu, W, Graupner, V, Sun, S W, Kowanetz, M, Hoang, T, Lin, W, Jotte, R M
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Combined Deficiency of Chromosome 7 Myeloid Tumor Suppressors Enhances Chemotherapy Resistance
Jotte, Matthew R. M., Martinez, Tanner C., Stoddart, Angela, Imgruet, Molly K., Nam, Henna S., Hu, Bonnie, Khan, Saira, An, Ningfei, McNerney, Megan E.
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC
Konduri, K., Spira, A. I., Jotte, R. M., Boyd, T., Gaffar, Y. A., Reynolds, C., Witta, S. E.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article
A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy
Ettinger, D. S., Jotte, R. M., Gupta, V., Allen, A. R., Oliver, J. W.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
Jotte, R. M., Conkling, P. R., Reynolds, C., Allen, A. R., Oliver, J. W.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article